Skip to content
Clinical Trials – home

Mitomycin: A Comprehensive Guide for Patients

13 / 23
trials open to patients / all trials
23+
Countries

In short

Mitomycin is a powerful drug being studied in clinical trials for its potential to treat a variety of medical conditions. This article explores how Mitomycin is being used in different types of clinical trials, including cancer treatment, eye surgeries, and urological procedures. We'll look at the drug's effectiveness, safety, and potential benefits for patients across multiple medical specialties.

What is Mitomycin?

Mitomycin, also known as Mitomycin C, is a powerful medication used in various medical treatments. It belongs to a class of drugs called antineoplastic antibiotics, which means it can fight cancer cells and prevent their growth. Mitomycin is derived from the Streptomyces caespitosus bacterium and has been used in medicine for several decades.

This drug is known by several other names, including:

  • Ametycine
  • MITO or MITO-C
  • Mitocin or Mitocin-C
  • Mitolem
  • Mitosol
  • Mitozytrex
  • Mutamycin or Mutamycine

Uses of Mitomycin

Mitomycin is used to treat various conditions, including:

  • Cancer: It is used in the treatment of several types of cancer, particularly colorectal cancer and anal canal cancer.
  • Glaucoma: Mitomycin is used during glaucoma surgery to prevent scarring and improve the success rate of the procedure.
  • Bladder Cancer: It's used in the treatment of superficial bladder cancer.
  • Urethral Stricture: Mitomycin is being studied for its potential in treating recurrent urethral strictures.

How Mitomycin Works

Mitomycin works by interfering with the DNA of cells, which prevents them from dividing and growing. This action is particularly effective against cancer cells, which tend to divide rapidly. In addition to its anti-cancer properties, Mitomycin also has the following effects:

  • It inhibits the growth of fibroblasts, which are cells involved in forming scar tissue.
  • It reduces the release of matrix proteins, which are important in tissue healing and scar formation.
  • It has anti-proliferative (stopping cell growth) and anti-scarring properties.

Administration Methods

Mitomycin can be administered in several ways, depending on the condition being treated:

  • Intravenous (IV) injection: The drug is injected directly into a vein, often used in cancer treatment.
  • Topical application: In eye surgeries, Mitomycin may be applied directly to the surgical site using a sponge.
  • Intravesical administration: For bladder cancer, the drug is introduced directly into the bladder through a catheter.
  • Intralesional injection: In some cases, Mitomycin may be injected directly into the affected tissue, such as in urethral stricture treatment.

Mitomycin in Cancer Treatment

Mitomycin plays a significant role in cancer treatment, particularly for colorectal and anal canal cancers. It is often used in combination with other treatments:

  • Chemoradiotherapy: Mitomycin is frequently combined with radiation therapy and other chemotherapy drugs like capecitabine or 5-fluorouracil. This combination has shown effectiveness in treating anal canal cancer.
  • Hyperthermic Intraperitoneal Chemotherapy (HIPEC): In some cases of advanced colorectal cancer, Mitomycin is used in a procedure called HIPEC, where the drug is heated and circulated in the abdominal cavity during surgery.

Mitomycin in Eye Surgery

Mitomycin is widely used in ophthalmology, particularly in glaucoma surgery. Its application in this field includes:

  • Trabeculectomy: This is a type of glaucoma surgery where Mitomycin is applied to prevent scarring and improve the success rate of the procedure.
  • Ahmed Glaucoma Valve Implantation: Research is being conducted to evaluate the effectiveness of Mitomycin in improving outcomes of this procedure.

Mitomycin in Urological Procedures

In urology, Mitomycin is used in several ways:

  • Bladder Cancer Treatment: It's administered directly into the bladder (intravesical therapy) to treat superficial bladder cancer.
  • Urethral Stricture Treatment: Research is ongoing to evaluate the effectiveness of injecting Mitomycin into the urethra after a procedure called visual internal urethrotomy to prevent the recurrence of urethral strictures.

Side Effects and Precautions

Like all medications, Mitomycin can cause side effects. These can vary depending on how the drug is administered and what it's being used to treat. Some potential side effects include:

  • Nausea and vomiting
  • Decreased blood cell counts, which can increase the risk of infection or bleeding
  • Fatigue
  • Skin reactions at the injection site
  • In eye surgeries, it may cause changes in vision or eye discomfort

It's important to discuss potential side effects with your healthcare provider before starting treatment with Mitomycin.

Ongoing Research

Researchers continue to study Mitomycin to find new uses and improve its effectiveness. Some areas of ongoing research include:

  • Comparing different methods of applying Mitomycin in eye surgeries to determine the most effective approach.
  • Evaluating the use of Mitomycin in combination with other treatments for various types of cancer.
  • Investigating the potential of Mitomycin in treating recurrent urethral strictures.

As research continues, our understanding of Mitomycin and its potential uses may expand, potentially leading to new treatments and improved outcomes for patients.

Questions people often ask

Conditions where Mitomycin is being studied

Each condition opens its own overview and trial list

Trials with Mitomycin

Recruiting trials first

See all 23 →
Quick filters
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).